Risk of death after first-time blood stream infection in incident dialysis patients with specific consideration on vascular access and comorbidity

Karl Emil Nelveg-Kristensen, Gunnar Hellmund Laier, James Goya Heaf, Karl Emil Nelveg-Kristensen, Gunnar Hellmund Laier, James Goya Heaf

Abstract

Background: The mortality following blood stream infection (BSI) and risk of subsequent BSI in relation to dialysis modality, vascular access, and other potential risk factors has received relatively little attention. Consequently, we assessed these matters in a retrospective cohort study, by use of the Danish nation-wide registries.

Methods: Patients more than 17 years of age, who initiated dialysis between 1.1.2010 and 1.1.2014, were grouped according to their dialysis modality and vascular access. Survival was modeled in time-dependent Cox proportional hazard analyses. Potential risk factors confined by a modified Charlson comorbidity index (MCCI), were subsequently assessed in stepwise selection models.

Results: At baseline, 764 patients received peritoneal dialysis (PD), and 434, 479, and 782 hemodialysis (HD) patients were dialyzed by use of arteriovenous fistulas (AVFs), tunneled catheters (TCs), and non-tunneled catheters (NTCs), respectively. We identified 1069 BSIs with an overall incidence rate of 17.7 episodes per 100 person years, and 216 BSIs occurred more than one time in the same patient. HRs of post BSI mortality relative to PD were 3.20 (95% CI 1.86-5.50; p < 0.001) with NTCs; whereas no associations were found for AVF and TC. The risk of subsequent BSIs was higher with NTCs [HR 2.29 (95% CI 1.09-4.82), p = 0.030], and no significant difference was found for AVF and TC, in relation to PD. There was an increased risk of both outcomes with TC relative to AVF [death: 1.57 (95% CI 1.07-2.29, P < 0.021); BSI: 1.78 (95% CI 1.13-2.83, P < 0.014], and risk of death was reduced in patients who changed to AVF after first-time BSI. The MCCI was significantly associated with the risk of subsequent BSI and post BSI death; however, only some of the variables contained in the index were found to be significant risk predictors when analyzed in the fitted model.

Conclusions: While NTC was the most predominant risk factor for subsequent BSI and post BSI mortality, AVF appeared protective.

Keywords: Blood stream infection; Dialysis; Dialysis modality; Risk factors; Vascular access.

Conflict of interest statement

Ethics approval and consent to participate

Retrospective, register-basted studies of anonymized data do not require ethical approval in Denmark. The current study was approved by the Danish Data Protection agency (Reg-84-2015) and the Danish Patient Safety Authority (No. 3–3013-1329/1). Consent to participate was not required in the current study. This was waivered by the Danish Data Protection Agency, as data was collected retrospectively by use of the Danish nationwide registries for scientific epidemiological research only, and as the collection of informed consent in this setting was impossible.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Distribution of causal microbiologic isolates at first-time BSI (a) and after more than two BSI episodes (b). CNS: coagulase negative staphylococci. The P-value for overall difference in distribution of microbiologic isolates between a and b were < 0.001
Fig. 2
Fig. 2
Risk of post BSI mortality in patients with a first-time BSI. Results from the adjusted time-dependent Cox proportional hazard analyses. IR: Incidence rate per 100 patient-years; HR: Hazard ratio for the risk of death after first time BSI. Patients without BSI are used as reference. AVF: arteriovenous fistula; TC: tunneled catheter; NTC: non-tunneled catheter; BSI: blood stream infection. Error bars illustrate 95% confidence intervals
Fig. 3
Fig. 3
Risk of blood stream infection (BSI) and death in the total study population and after first-time BSI. Results from the adjusted time-dependent Cox proportional hazard analyses. IR: Incidence rate per 100 patient-years; HR: Hazard ratio for the risk of BSI and all-cause mortality, as well as subsequent BSI episodes and post BSI mortality after first-time BSI. Patients receiving peritoneal dialysis (PD) are used as reference. AVF: arteriovenous fistula; TC: tunneled catheter; NTC: non-tunneled catheter; BSI: blood stream infection. Error bars illustrate 95% confidence intervals

References

    1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272. doi: 10.1016/S0140-6736(13)60687-X.
    1. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80:1258–1270. doi: 10.1038/ki.2011.368.
    1. Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011) 2015;5:2–7. doi: 10.1038/kisup.2015.2.
    1. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US renal data system 2009 annual data report. Am J Kidney Dis. 2010;55:S1–420. doi: 10.1053/j.ajkd.2009.10.009.
    1. Skov Dalgaard L, Norgaard M, Jespersen B, et al. Risk and prognosis of bloodstream infections among patients on chronic hemodialysis: a population-based cohort study. PLoS One. 2015;10:e0124547. doi: 10.1371/journal.pone.0124547.
    1. Bray BD, Boyd J, Daly C, et al. Vascular access type and risk of mortality in a national prospective cohort of haemodialysis patients. QJM. 2012;105:1097–1103. doi: 10.1093/qjmed/hcs143.
    1. Nielsen LH, Jensen-Fangel S, Benfield T, et al. Risk and prognosis of Staphylococcus aureus bacteremia among individuals with and without end-stage renal disease: a Danish, population-based cohort study. BMC Infect Dis. 2015;15:6. doi: 10.1186/s12879-014-0740-8.
    1. Hayes WN, Tennankore K, Battistella M, Chan CT. Vascular access-related infection in nocturnal home hemodialysis. Hemodial Int. 2014;18:481–487. doi: 10.1111/hdi.12140.
    1. Williams VR, Quinn R, Callery S, Kiss A, Oliver MJ. The impact of treatment modality on infection-related hospitalization rates in peritoneal dialysis and hemodialysis patients. Perit Dial Int. 2011;31:440–449. doi: 10.3747/pdi.2009.00224.
    1. Koch M, Kohnle M, Trapp R, Haastert B, Rump LC, Aker S. Comparable outcome of acute unplanned peritoneal dialysis and haemodialysis. Nephrol Dial Transplant. 2012;27:375–380. doi: 10.1093/ndt/gfr262.
    1. Lafrance JP, Rahme E, Iqbal S, et al. Association of dialysis modality with risk for infection-related hospitalization: a propensity score-matched cohort analysis. Clin J Am Soc Nephrol. 2012;7:1598–1605. doi: 10.2215/CJN.00440112.
    1. Wang IK, Chang YC, Liang CC, et al. Bacteremia in hemodialysis and peritoneal dialysis patients. Intern Med. 2012;51:1015–1021. doi: 10.2169/internalmedicine.51.7111.
    1. Chan KE, Warren HS, Thadhani RI, et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol. 2012;23:1551–1559. doi: 10.1681/ASN.2012010050.
    1. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC. Dialysis surveillance report: National Healthcare Safety Network (NHSN)-data summary for 2006. Semin Dial. 2008;21:24–28. doi: 10.1111/j.1525-139X.2007.00379.x.
    1. Fysaraki M, Samonis G, Valachis A, et al. Incidence, clinical, microbiological features and outcome of bloodstream infections in patients undergoing hemodialysis. Int J Med Sci. 2013;10:1632–1638. doi: 10.7150/ijms.6710.
    1. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol. 2005;26:534–539. doi: 10.1086/502580.
    1. Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int. 1998;54:1684–1689. doi: 10.1046/j.1523-1755.1998.00134.x.
    1. Nissenson AR, Dylan ML, Griffiths RI, et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis. 2005;46:301–308. doi: 10.1053/j.ajkd.2005.04.019.
    1. Li Y, Friedman JY, O'Neal BF, et al. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol. 2009;4:428–434. doi: 10.2215/CJN.03760708.
    1. Heaf J. The Danish Nephrology Registry. Clin Epidemiol. 2016;8:621–627. doi: 10.2147/CLEP.S102649.
    1. Voldstedlund M, Haarh M, Molbak K, MiBa Board of R. The Danish microbiology database (MiBa) 2010 to 2013. Euro Surveill. 2014;19.
    1. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263–268.
    1. Nordic Medico-Statistical Committee . Classification of Surgical Procedures, version 1.15. 2010 no. 93. 2010.
    1. Perl J, Wald R, McFarlane P, et al. Hemodialysis vascular access modifies the association between dialysis modality and survival. J Am Soc Nephrol. 2011;22:1113–1121. doi: 10.1681/ASN.2010111155.
    1. Dalrymple LS, Mohammed SM, Mu Y, et al. Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis. Clin J Am Soc Nephrol. 2011;6:1708–1713. doi: 10.2215/CJN.10151110.
    1. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 2006;21:1024–1031. doi: 10.1093/ndt/gfi104.
    1. Ascher E, Hingorani A. The Dialysis outcome and quality initiative (DOQI) recommendations. Semin Vasc Surg. 2004;17:3–9. doi: 10.1053/j.semvascsurg.2003.11.009.
    1. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis. 2004;44:779–791. doi: 10.1016/S0272-6386(04)01078-9.
    1. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med. 1997;127:275–280. doi: 10.7326/0003-4819-127-4-199708150-00003.
    1. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis. 1999;34:1114–1124. doi: 10.1016/S0272-6386(99)70018-1.
    1. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int. 1999;55:1081–1090. doi: 10.1046/j.1523-1755.1999.0550031081.x.
    1. Jean G, Charra B, Chazot C, et al. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron. 2002;91:399–405. doi: 10.1159/000064279.
    1. Sedlacek M, Gemery JM, Cheung AL, Bayer AS, Remillard BD. Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am J Kidney Dis. 2007;49:401–408. doi: 10.1053/j.ajkd.2006.12.014.
    1. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol. 2004;15:1038–1045. doi: 10.1097/01.ASN.0000119144.95922.C4.
    1. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869–876.
    1. Tanriover B, Carlton D, Saddekni S, et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int. 2000;57:2151–2155. doi: 10.1046/j.1523-1755.2000.00067.x.
    1. Tokars JI, Light P, Anderson J, et al. A prospective study of vascular access infections at seven outpatient hemodialysis centers. Am J Kidney Dis. 2001;37:1232–1240. doi: 10.1053/ajkd.2001.24527.
    1. Unver S, Atasoyu EM, Evrenkaya TR, Ardic N, Ozyurt M. Risk factors for the infections caused by temporary double-lumen hemodialysis catheters. Arch Med Res. 2006;37:348–352. doi: 10.1016/j.arcmed.2005.07.010.
    1. Gauna TT, Oshiro E, Luzio YC, Paniago AM, Pontes ER, Chang MR. Bloodstream infection in patients with end-stage renal disease in a teaching hospital in Central-Western Brazil. Rev Soc Bras Med Trop. 2013;46:426–432. doi: 10.1590/0037-8682-0060-2013.
    1. Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012;14:302–311. doi: 10.1093/eurjhf/hfs007.
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. doi: 10.1056/NEJMra011775.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera